The expression of Foxa2 and Lmx1a endowed 5F-iNPCs with midbrain identity and dramatically increased the yield of TH+ neurons (Fig. S1, Fig. S2), suggesting that these two factors could be used to improve the iNPCs-based cell therapy in PD. The gene discussed is FOXA2; the disease is Parkinson disease.